Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01756053 · ClinicalTrials.gov registry record · Phase 2
Effects of ABT-089 on Smoking Abstinence Symptoms and Reward
A Phase 2 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 2
- Development phase
- 17
- Enrollment target
NCT01756053: Clinical Trial Phase 2 study, sponsored by University of Pennsylvania.
NCT01756053 is a Phase 2 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 17 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01756053, a Phase 2 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 17 participants
- Enrollment target
Study Summary
This Phase IIa within-subject, cross-over pilot study will evaluate the effects of ABT-089 (an experimental medication not approved by the FDA) when administered as 40mg oral once daily dose for 10 days, compared to placebo, on the following: abstinence-induced cognitive deficits, smoking withdrawal, smoking urges, smoking reward, and a brief, monitored quit attempt (\~4 days). The key cognitive domains include: working memory, sustained attention, and response inhibition.
Interventions
- DRUG Placebo
- DRUG ABT-089
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2013-03 |
| Est. Completion | 2014-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01756053
The ClinicalTrials.gov registry entry for NCT01756053 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01756053 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01756053 about?
NCT01756053 is a clinical study titled "Effects of ABT-089 on Smoking Abstinence Symptoms and Reward". This Phase IIa within-subject, cross-over pilot study will evaluate the effects of ABT-089 (an experimental medication not approved by the FDA) when administered as 40mg oral once daily dose for 10 days, compared to placebo, on the following: abstinence-induced cognitive deficits, smoking withdrawal...
What is the current status of trial NCT01756053?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 17 participants. The study started on 2013-03. Estimated completion is 2014-01.
What interventions are being tested in trial NCT01756053?
The interventions under investigation include: Placebo (DRUG), ABT-089 (DRUG).
Who is sponsoring clinical trial NCT01756053?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.